期刊文献+

奥美拉唑对氯吡格雷的脑梗死二级预防作用的影响 被引量:2

下载PDF
导出
摘要 目的探讨奥美拉唑对氯吡格雷的脑梗死二级预防作用的影响。方法选择2009年1月1日至2009年12月31日该院口服氯吡格雷(波立维75 mg口服,1次/天)进行脑梗死二级预防的急性脑梗死患者144例,A组(n=91)单用氯吡格雷;B组(n=53)予氯吡格雷联合奥美拉唑(洛赛克10 mg,2次/天)。对其临床资料及发病后30 d内的脑梗死复发情况进行分析。结果 A组复发4例(4.4%),B组复发8例(15.1%),B组脑梗死复发率明显高于A组(P=0.044,OR=4.601,95%CI:1.045~20.259)。结论奥美拉唑致氯吡格雷的脑梗死二级预防作用明显减弱,增加脑梗死复发率。
出处 《重庆医学》 CAS CSCD 北大核心 2011年第25期2567-2568,共2页 Chongqing medicine
  • 相关文献

参考文献8

  • 1Savi P,Pereillo JM,Uzabiaga MF,et al.Identification and biological activity of the active metabolite of clopidogrel[J].Thromb Haemost,2000,84(5):891-896.
  • 2Gilard M,Amaud B,Cornily JC,et al.Influence of omeprasole on the antiplatelet action of clopidogrel associated with aspirin:the randomized,doubleblind OCLA(Omeprazole Clop-idogrel Aspirin)study[J].J Am Coll Cardiol,2008,51(3):256-260.
  • 3Juurlink DN,Gomes T,Ko DT,et al.A population-based study of the drug interaction between proton pump inhibitors and clopidogrel[J].CMAJ,2009,180(7):699-700.
  • 4各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379-380. 被引量:33058
  • 5Hollopeter G,Jantzen HM,Vincent D,et al.Identification of the platelet ADP receptor targeted by antithrombotic drugs[J].Nature,2001,409(6817):202-207.
  • 6Gerson LB,Triadafilopoulos G.Proton pump inhibitors and their drug interactions:an evidence-based approach[J].Eur J Gastroenterol Hepatol,2001,13(5):611-616.
  • 7Miao J,Liu R,Li Z,et al.Cytochrome P-450 polymorphisms and response to clopidogrel[J].N Engl J Med,2009,360(4):363-375.
  • 8Brandt JT,Close SL,Iturria SJ,et al.Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel[J].J Thromb Haemost,2007,5(12):2429-2436.

共引文献33057

同被引文献36

  • 1汤丽霞,李江丽,马兰煌,谭斯艺.重症监护病房获得性细菌感染临床调查[J].中华医院感染学杂志,2007,17(3):267-268. 被引量:27
  • 2刘坤,李有信,杜晓玲.耐万古霉素肠球菌医院感染危险因素分析[J].中华医院感染学杂志,2007,17(8):1000-1002. 被引量:17
  • 3Schalm SW, Heat heote J , Cianiara J , et al . Lamivudine and alpha intederon combination treatment of patients with chronic hepatitis B in- fection:a randomised trial[J] .Gut,2000,46(4):562.
  • 4$wanston WH. Methicillin resistant Staphylococcus aureus[J]. West In- dia Med J, 1999,48(1) :20.
  • 5Fridkin SK, Lawton R, Edwards JR, et al. Monitoring antimicrobial use and resistance', oomparison with a national benchmark on reducing van- eomyoin use and vancomyoin-resistant enterococci[J]. Emerg Infect Dis, 2002,8(7) :702.
  • 6Shlaes DM, Gerding DN, John J-F, et 81 . Society for Healthcare Epi- demiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrebial Resistance:guidelines for the prevention of antimicrebial resistance in hospitals[ J]. Infect Control Hosp Epidcmiol, 1997,18(4) :275.
  • 7Dellit TH, Owens RC, McGowan JE, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicro- bial stewardship[ J. Clin Infect Dis, 2007,44(2) : 159.
  • 8Kushner FG,Hand M, Smith SJ,et al. 2009 focused up dates:ACC/AHA guidelines for the management of pa tients with ST elevation myocardial infarction (updatin the 2004 guideline and 2007 focused update) and ACC/ AHA/SCAI guidelines on percutaneous coronary inter vention (updating the 2005 guideline and 2007 focused up date) a report of the American College of Cardiolog3 Foundation/American Heart Association Task Force or Practice Guidelines[J]. J Am Coll Cardiol, 54 (23) : 2205 2241.
  • 9Angiolillo DJ,F'ernandez-Ortiz A, Bernardo E, et al. Vari- ability in individual responsiveness to elopidogrel - Clinical implications, management, and future perspectives [J]. J Am Coll Cardiol,2007,49(14) :1505 1516.
  • 10Miao J, Liu R, Li Z. Cytochrome P 450 polymorphisms and response to clopidogrel[J]. N Engl J Med, 2009,360 (21) : 2250-2251.

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部